A detailed history of Bayesian Capital Management, LP transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 12,621 shares of ACET stock, worth $11,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,621
Previous 24,421 48.32%
Holding current value
$11,611
Previous $29,000 37.93%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.07 - $1.63 $12,626 - $19,234
-11,800 Reduced 48.32%
12,621 $18,000
Q2 2024

Aug 14, 2024

SELL
$1.21 - $2.4 $16,940 - $33,600
-14,000 Reduced 36.44%
24,421 $29,000
Q1 2024

May 15, 2024

BUY
$1.76 - $3.45 $67,620 - $132,552
38,421 New
38,421 $90,000
Q4 2022

Feb 14, 2023

BUY
$7.72 - $21.27 $172,943 - $476,490
22,402 New
22,402 $200,000

Others Institutions Holding ACET

About Adicet Bio, Inc.


  • Ticker ACET
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,030,800
  • Market Cap $36.8M
  • Description
  • Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...
More about ACET
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.